EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Françoise Derouane iD, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal iD, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse und 5 weitere

Molecular Oncology · 2025-08 · 19 (8) · 2330-2347

DOI: 10.1002/1878-0261.13813 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Molecular Oncology, online erschienen am 06.02.2025. Verfasst von Françoise Derouane und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Hospital Leuven, Belgium. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Lymphocytes, Tumor-Infiltrating, Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wallonie-Recherche SPW - WALInnov.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) play a central role in early‐stage breast cancer (BC) and are associated with chemoresistance, stemness, and invasion. The objective of this study was two fold: (a) by investigating the predictive value of EMT and TILs, we aimed to estimate the chance of achieving a response after neoadjuvant chemotherapy (NAC) and (b) to evaluate the potential changes of EMT and TILs in BC upon NAC. Using bulk RNA sequencing and immunofluorescence (IF) for EMT (E‐cadherin and vimentin) and lymphocyte markers (CD3, CD8, FOXP3), we analyzed pre‐ and post‐NAC tumor samples from 100 early‐BC patients treated with NAC. For each BC molecular subtype, we compared the expression of EMT and TILs, at the RNA and protein level, between responding and non‐responding tumors. Paired analysis of pre‐ and post‐NAC samples was performed for patients with residual disease after NAC. RNA sequencing of pre‐ and post‐NAC samples identified significant differences in EMT‐related and inflammation‐related gene expression between non‐responding (RCB‐II/III) and responding (RCB‐0/I) tumors. Increased EMT‐related marker expression was observed after NAC in cases with residual disease, in particular in the luminal subtype. Characterization of TILs in pre‐NAC samples showed substantially more CD3 + CD8‐FOXP3‐lymphocytes in responding HER2+ tumors compared with non‐responding. Paired analyses of pre‐ and post‐NAC samples demonstrated higher levels of CD3 + CD8 + FOXP3‐lymphocytes in residual luminal and triple‐negative BC and higher levels of CD3 + CD8‐FOXP3‐lymphocytes in residual triple‐negative BC compared with other subtypes of lymphocytes. We found that there is an unmet clinical need for reliable biomarkers to predict response to NAC in BC. Our results suggest that an upregulation of the EMT gene signature in diagnostic biopsies is associated with poor response to NAC in early BC, across all subtypes. Additionally, changes in EMT and in the TIL population occur in residual tumors after NAC. These findings could help to personalize future NAC and adjuvant treatment regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionLymphocytes, Tumor-InfiltratingBreast NeoplasmsTriple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyChemotherapy, AdjuvantNeoplasm StagingBreastBiopsyTreatment OutcomeGene Expression Regulation, NeoplasticHumansFemaleAdultMiddle AgedAged

Stichwörter der Autor:innen

EMTTILsearly breast cancerlymphocytesneoadjuvant chemotherapy

Autor:innen und Institutionen

  • Department of Medical Oncology, University Hospital Leuven, Belgium.
  • Pole of Medical Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, Belgium.
  • Center for Applied Molecular Technologies (CTMA), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, Belgium.
  • Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Department of Pathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Pole of Morphology (MORF), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, Belgium.

ORCID-Profile: Françoise Derouane, Mieke Van Bockstal, Cyril Corbet, François P Duhoux

Förderung

  • Wallonie-Recherche SPW - WALInnov

Zitieren

APA

Derouane, F., Ambroise, J., van Marcke, C., Van Bockstal, M., Berlière, M., Galant, C., Dano, H., Lougué, M., Benidovskaya, E., Jerusalem, G., Bours, V., Josse, C., Thiry, J., Daumerie, A., Bouzin, C., Corbet, C., & Duhoux, F. P. (2025). Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes. Molecular Oncology, 19(8), 2330-2347. https://doi.org/10.1002/1878-0261.13813

Vancouver

Derouane F, Ambroise J, van Marcke C, Van Bockstal M, Berlière M, Galant C, et al. Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes. Molecular Oncology. 2025;19(8):2330-2347. doi:10.1002/1878-0261.13813

BibTeX
@article{Derouane2025,
  author = {Derouane, Françoise and Ambroise, Jérôme and van Marcke, Cédric and Van Bockstal, Mieke and Berlière, Martine and Galant, Christine and Dano, Hélène and Lougué, Médina and Benidovskaya, Elena and Jerusalem, Guy and Bours, Vincent and Josse, Claire and Thiry, Jérôme and Daumerie, Aurélie and Bouzin, Caroline and Corbet, Cyril and Duhoux, François P},
  title = {Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes},
  journal = {Molecular Oncology},
  year = {2025},
  volume = {19},
  number = {8},
  pages = {2330--2347},
  doi = {10.1002/1878-0261.13813}
}
Kostenlos starten →